Loss of function mutation in FBXW7, an E3 ubiquitin ligase, is associated with good prognosis and early glucocorticoid treatment response in childhood T-cell acute lymphoblastic leukemia (T-ALL) by unknown mechanisms. Here, we show that FBXW7 targets the glucocorticoid receptor a (GRa) for ubiquitylation and proteasomal degradation in a manner dependent on glycogen synthase kinase 3 b-mediated phsophorylation. FBXW7 inactivation caused elevated GRa levels, and enhanced the transcriptional response to glucocorticoids. There was significant enhancement of GR transcriptional responses in FBXW7-deficient cell lines and primary T-ALL samples, in particular, for those pro-apoptotic regulatory proteins, BIM and PUMA. Reduced FBXW7 expression or function promoted glucocorticoid sensitivity, but not sensitivity to other chemotherapeutic agents used in T-ALL. Moreover, this was a general feature of different cancer cell types. Taken together, our work defines GRa as a novel FBXW7 substrate and demonstrates that favorable patient prognosis in T-ALL is associated with FBXW7 mutations due to enhanced GRa levels and steroid sensitivity. These findings suggest that inactivation of FBXW7, a putative tumor suppressor protein, may create a synthetic lethal state in the presence of specific anticancer therapies.
INTRODUCTION
The F-box protein FBXW7 forms an SCF (Skp1/Cul1/F-box) type of E3 ubiquitin ligase complex that targets various proteins for ubiquitylation and proteasomal degradation. SCF FBXW7 regulates cell cycle progression and differentiation, and depending on the cell type, its inactivation results in deregulated expression of oncoproteins c-Myc, cyclin E, c-Jun, Mcl1 and Notch1. 1 Cumulative evidence supports a critical function for FBXW7 in the development of T-cell acute lymphoblastic leukemia (T-ALL), where it is frequently inactivated by mutation. [2] [3] [4] [5] [6] [7] [8] [9] Surprisingly, the presence of FBXW7 mutations in T-ALL defines a subgroup of patients characterized by good response to induction chemotherapy with glucocorticoids (GCs) and a more favorable outcome. [2] [3] [4] [5] [6] [7] [8] [9] The ability of GCs to specifically induce apoptosis in malignant lymphoid cells has led to their inclusion in almost all chemotherapy protocols for lymphocytic malignancies. GC response, after the first week of treatment with prednisolone has remained one of the strongest markers of prognosis and is used for treatment stratification in childhood ALL. 10, 11 GC resistance is a welldocumented feature of relapse. 12, 13 GCs mediate antiproliferative and pro-apoptotic effects in lymphocytes through activation of the glucocorticoid receptor (GR), 14 a ubiquitously expressed nuclear transcription factor that regulates the transcription of GC responsive genes.
14 Several GR isoforms exist as a result of alternative splicing and the use of multiple promoters. 15 Upon binding to GCs, the predominant isoform, glucocorticoid receptor a (GRa), dissociates from heatshock proteins in the cytoplasm and translocates into the nucleus, where it interacts directly with GC response elements, resulting in transactivation or transrepression of specific target genes. 16 Here, we report that FBXW7 mediates ubiquitylation and proteasomal degradation of GRa in a glycogen synthase kinase 3 (GSK3) b phosphorylation-dependent manner. Inactivation of FBXW7 enhances GRa stability and activity, promoting the transcription of GR-responsive target genes, including the activation of pro-apoptotic genes. Altogether, our work defines GRa as a novel FBXW7 substrate and further demonstrates that inactivation of FBXW7 leads to elevated sensitivity to the cytostatic effects of GCs in T-ALL.
MATERIALS AND METHODS

Cell culture, transfections and treatments
Tumor-derived cell lines were cultured according to the guidelines at the American Type Culture Collection. The following cell lines were used in this study: HEK293, HeLa, HCT116, MiaPaCa, Peer, Molt4, K562. HCT116 FBXW7-WT and FBXW7 knockout cells was a gift from B Vogelstein, and were grown in McCoy's medium. Media was supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U per ml penicillin, and 100 g per ml streptomycin. For all experiments described in this study, xenograft cells were retrieved from cryostorage and resuspended in QBSF-60 medium (Quality Biological, Gaithersburg, MD, USA) supplemented with Flt-3ligand (20 ng/ml; Amgen, Thousand Oaks, CA, USA), penicillin (100 units/ml), streptomycin (100 Ag/ml) and L-glutamine (2 mmol/l; QBSF-60/F). Because xenograft cells require high cell density and exhibit prolonged population doubling times, the two most informative time points were used in the cycloheximide (CHX) chase experiments. Transient plasmid transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocols. Human small interfering RNA (siRNA) oligonucleotides directed against FBXW7 have been described previously. 17 siRNA transfections were carried out using the Amaxa nucleofector II (Lonza, Switzerland) as recommended by the manufacturer (Lonza). pLentiLox3.7 lentiviral vectors expressing small hairpin RNAs (shRNAs) against FBXW7 or a scrambled control, were transfected into 293T cells along with the vectors of VSVG, RSV-REV and pMDLg/pRPE, to generate shFBXW7 lentiviruses. Peer and K562 cells were transduced with lentiviruses with a multiplicity of infection of 10, and incubated in roswell park memorial institute medium-1640 media containing polybrene 8 mg/ml. Transduced cells were sorted based on GFP expression using a cell sorter (BD FacsAria; BD, Franklin Lakes, NJ, USA). The Alamar Blue assay was used to determine cell viability as described. 18 Treatments with doxorubicin, methotrexate, vincristine, dexamethasone (Pfizer, Groton, CT, USA), MG-132 (Enzo Life Sciences, Exeter, UK) and BIO (Tocris Bioscience, Bristol, UK) were carried out as indicated. For protein stability experiments, cells were treated with 100 mg per ml CHX (Enzo Life Sciences) as indicated.
Flag-FBXW7 and HA-tagged ubiquitin constructs were described previously. 17 Myc-DDK-GRa plasmid was purchased from OriGene (Rockville, MD, USA). Flag-FBXW7-R465H, -R479Q, -R505C and Myc-DDKGRa S404A mutants were generated with the QuikChange XL site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions.
Western blotting, immunoprecipitation and in vivo ubiquitylation assay
The following primary antibodies were used: anti-HA (Y11), anti-MYC tag (9E10) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Actin, antiFlag (M2) (Sigma-Aldrich, Sydney, Australia), anti-tubulin, anti-FBXW7 (ab12292-100) (Abcam, Cambridge, UK); anti-Mcl1 (Y37) (Cell Signaling, Danvers, MA, USA); anti-GR (BD biosciences, Franklin Lakes, NJ, USA); antiBim (AB17003, anti-Puma (AB4510) (Merck Millipore, Carlsbad, MA, USA). For immunoprecipitation studies, cells were lysed in NP-40 buffer with 150 mM NaCl and protease inhibitors (Roche, Basel, Switzerland). For in vivo ubiquitylation assays, cells were transfected with the indicated plasmids for 36 h following dexamethasone and proteasome inhibitor, MG-132 treatment then lysed under denaturing conditions. Two mg of protein was immunoprecipitated with specified antibodies. After immunoprecipitation, the samples were washed and analyzed by western blot using anti-HA antibody.
Microarray, quantitative real-time-PCR (qRT-PCR) and reporter assays
Total RNA from siRNA/shRNA-transduced was extracted using RNeasy kit (Qiagen, Germantown, CA, USA). Complementary DNA was synthesized using the SuperScript III First-Strand Synthesis System (Invitrogen, CA, USA) according to the manufacturer's instructions. qRT-PCR was performed in triplicate and analyzed on an ABI 7,900 RT-PCR system. Glyceraldehyde 3-phosphate dehydrogenase was used as a reference (TaqMan glyceraldehyde 3-phosphate dehydrogenase control reagents, Applied Biosystems, Foster City, CA, USA). PCR primer sequences are available from the authors upon request. Comparative C T values were normalized against glyceraldehyde 3-phosphate dehydrogenase mRNA according to the manufacturer's protocol (ABI PRISM User Bulletin no. 2).
The luciferase reporter assay was performed in 293T cells transduced with pGL4.36-MMTV (Murine Mammary Tumor Virus)-luciferase plasmid (Promega, Madison, WI, USA). 293T cells were stably transfected with pGL4.36-MMTV-luciferase reporter and used for further analysis. The Renilla luciferase vector pRL-TK (Promega) was used for normalization. Luciferase activities were quantified in a luminometer (VICTOR3, PerkinElmer, Waltham, MA, USA) using the Dual-Luciferase Reporter Assay System according to the manufacturer's protocol (Promega). Fold change was averaged from three separate experiments performed in triplicate.
Labeling and hybridization to Affymetrix Human Gene 1.0 Arrays was performed by the Ramaciotti Center for Gene Function Analysis (University of New South Wales, Sydney, Australia) according to the manufacturer's protocol. Hybridization was performed in duplicate. Raw cell files were processed for background correction and quantile normalization using the robust multiarray averaging method and GenePattern software; Broad Institute, Cambridge, MA, USA (http://pwbc.garvan.unsw.edu.au/gp/pages/ index.jsf) with 'expression file creator' module to generate the gene expression data set (.gct file).
Differential expression analysis was performed using GenePattern software with the 'ComparativeMarkerSelection' module, using a number of permutations of 0 to calculate asymptotic P-values, and two-sided t-test to calculate P-values. The obtained data matrix file was imported into 'ComparativeMarkerSelectionViewer' module for further analysis. Genes significantly upregulated were generated by filtering using a false discovery rate p0.1 and P-value o0.01 and fold change 41.5.
Gene set enrichment analysis was performed as described using the gene sets from the molecular signatures database. We ranked genes by a decreasing moderated t statistic, created a pre-ranked list and used this as input for running Gene set enrichment analysis in pre-ranked mode with 1,000 permutations. We compared the moderated t statistic to the 'C5_all' collection of curated gene sets from molecular signatures database 1.0. The following parameters were used: probe set collapse ¼ true; permutation: gene set, number of permutations ¼ 1,000. Gene set size: 15ono500. Gene sets were compared using the normalized enrichment score and deemed significant at 0.05 with a false discovery rate less than 0.25.
RESULTS
Increased FBXW7 expression conferred sensitivity to GC
To address the role of FBXW7 inactivation in conferring sensitivity to apoptosis, we analyzed the responses of human T-ALL cell lines with wild-type FBXW7 to increased doses of chemotherapeutic agents used in the induction phase of treatment of standard risk ALL: doxorubicin, methotrexate, vincristine and GCs. Molt4 and Peer T-ALL cell lines, with wild-type FBXW7, 7 were transfected with siRNA duplexes targeting a common region shared by the all FBXW7 isoforms or scrambled control siRNAs. Silencing of FBXW7 was confirmed by RT-PCR analysis in each cell line (Supplementary Figure S1A) . No significant change in viability was observed in FBXW7-silenced cells following the treatment with vincristine, methotrexate or doxorubicin ( Figure 1a ). Although both Molt4 and Peer T-ALL cell lines display GC resistance, we could show that at the IC20 there was a 0.7 log lower GC concentration (P ¼ 0.0014) when FBXW7 expression was reduced. The only GC sensitive T-ALL cell line described (CEM-C7-14) 19 contained point mutation in substrate binding region of FBXW7, 7 therefore, was excluded from the analysis. Importantly, GC sensitive solid cancer cell lines from cervical (HeLa) and pancreatic (MiaPaCa) cancers transfected with FBXW7-specific siRNA duplexes also exhibited increased sensitivity to dexamethasone (Figure 1b) .
To improve the efficiency of FBXW7 gene silencing in leukemic cells, lentiviral vectors expressing FBXW7-shRNA were generated, and the effect of dexamethasone on cell viability was examined in leukemia cell lines, K562 and Peer, transduced with the shFBXW7 or scrambled control viruses. Knockdown of FBXW7 using the shFBXW7 lentiviral vector was more effective than the transiently transfected siFBXW7 oligos (Supplementary Figure S1B) . Reduced FBXW7 expression in K562 and Peer cells produced a small, but significantly enhanced GC sensitivity ( Figure 1c and Supplementary Figure S2 ). Similar results were found when we assessed the ability of dexamethasone-treated FBXW7-deficient K562 cells to grow as colonies in semisolid media, as compared with the control (Figure 1d ).
FBXW7 regulates GRa protein stability
To test if the enhanced response to dexamethasone correlates with the expression level of the glucocorticoid receptor, steadystate protein level of glucocorticoid receptor was examined in FBXW7-silenced cells following dexamethasone treatment. As To specifically address whether silencing of FBXW7 increased GRa protein levels due to reduced GRa protein degradation, we next performed CHX-chase experiments in leukemic cell lines with wild-type FBXW7, Peer, following dexamethasone treatment. Indeed, silencing of FBXW7 using an FBXW7 shRNA (shFBXW7), as compared with shRNA scramble control (sh control), significantly increased GRa protein half-life from 3.8 to 5.2 h (Figure 2b ). Moreover, FBXW7 silencing also increased GRa protein half-life in another leukemia cell line, K562 cells from 7.5 to 9.8 h (Figure 2b ). To further evaluate the effect of FBXW7 on GR stability, we analyzed GRa degradation in colon carcinoma HCT116 FBXW7-knockout cells reconstituted with WT-FBXW7. As shown in Figure 2c , expression of WT-FBXW7 reduced GRa protein half-life, compared with cells expressing empty vector. Similar data were obtained in HEK293 cells (Supplementary Figure S3C) . To determine whether T-ALL-derived FBXW7 mutations affect the stability of GR protein in primary human leukemic cells, we used a panel of previously described T-ALL xenografts [20] [21] [22] and performed CHX-chase experiments of GRa protein following dexamethasone treatment. As shown in Figure 2d , the T-ALL xenograft with an FBXW7 mutation (ALL-27) showed a marked increase in GR stability, as compared with the xenografts with WT-FBXW7 (ALL-30, 16, 31).
As FBXW7 binds to its E3 ubiquitin ligase substrates through interaction between a b-propeller structure formed by its WD40 repeats and a CDC4 phosphodegron motif in the substrate, 23, 24 we next investigated whether FBXW7 could directly interact with GRa in vivo. We performed FBXW7-GRa coimmunoprecipitation assays in HEK293 cells transfected with an expression vector encoding WT-FBXW7 or an F-box deletion mutant of FBXW7 (FBXW7-DF ), which is unable to interact with the SCF complex, but is still capable of binding to substrates. FBXW7 was immuno-purified from cells treated with 10 mM dexamethasone, and GRa interaction was examined by immunoblot analysis. As shown in Figure 3a , GRa copurified with WT-FBXW7 and FBXW7-DF. Reciprocal 30, 16, 31 ). Xenograft cells were retrieved from cryostorage, exposed to dexamethasone (10 mM, 1 h), and subjected to CHX-chase analysis. Tubulin protein level is shown as a control for loading. Figure S4A) . To directly test whether GRa is an ubiquitylation target of FBXW7, we performed in vivo ubiquitylation assays by co-transfecting HEK293 cells with expression vectors for FBXW7, GRa and HA-ubiquitin. Expression of FBXW7 induced a significant increase in ubiquitin À conjugated GRa in vivo (Figure 3b ). To determine whether the FBXW7 arginine mutants commonly identified in primary T-ALL specimens 7 interfere with the formation of polyubiquitin chains on GRa, we performed in vivo ubiquitylation assays in HCT116 FBXW7-knockout cells transfected with either a WT-FBXW7 or with specific T-ALL-derived FBXW7 mutants R456H, R479Q and R505C. All FBXW7 mutants were severely deficient in polyubiquitylating GRa as compared with WT-FBXW7 (Figure 3c) . These results, which were also recapitulated in HEK293 cells (Supplementary Figure S4B) , supported the conclusion that T-ALL-derived FBXW7 mutations are not able to promote GRa ubiquitylation.
Phosphorylated GRa is degraded by FBXW7 Ubiquitylation and proteasomal degradation of FBXW7 E3 ubiquitin ligase substrates commonly requires prior phosphorylation of the CDC4 phosphodegron motif on serine or threonine residues by GSK3. 1, 25 GSK3b has previously been reported to phosphorylate GRa on serine 404 (S404), which correlated with a decrease in GR protein levels. 26 The amino acid sequence surrounding GRa S404 resembled a highly conserved CDC4 phosphodegron consensus motif (Figure 4a ). To investigate whether FBXW7 promoted GRa ubiquitylation and degradation in a GSK3b phosphorylation-dependent manner, HEK293 cells were treated with the pharmacological GSK3b inhibitor, BIO, following transient transfection with GRa, HA-ubiquitin and WT-FBXW7 isoforms a or g. Different isoforms of FBXW7 were used, as there is evidence that substrates that lack a second phosphogroup within the phospho-degron might require different FBXW7 isoforms. 27 Inhibition of GSK3b activity with BIO markedly impaired polyubiquitylation of GRa by FBXW7 (Figure 4b) . We next created a GRa mutant, in which the serine residue at position 404 was replaced by alanine (S404A). As shown in Figure 4c , the S404A GRa mutant was not efficiently ubiquitylated by FBXW7. Moreover, in CHX-chase experiments, we found that GRa protein half-life was markedly increased in cells transfected with the GRa S404A mutant, compared with cells transfected with the WT GRa (Figure 4d ).
Reduced FBXW7 expression enhances GC transcriptional response As GC-induced cytostatic cellular effects depend on the transcriptional activation or repression of GR-responsive target genes, 28, 29 we next examined the influence of the FBXW7 inactivation on GR transcriptional activity. Transient transfection of HEK293 cells with a MMTV luciferase reporter construct containing a GR-responsive promoter, 30 and shRNA against FBXW7 caused a significant Polyubiquitylated GRa conjugates were detected by western blot analysis with anti-HA antibodies as previously described. 7 (c) in vivo ubiquitylation of GRa in HCT116 FBXW7-negative cells. Cells were cotransfected with Myc-DDK-tagged GRa, HA-tagged ubiquitin, and either Flag-tagged FBXW7 or different Flag À tagged arginine mutant versions of FBXW7 expression plasmids, or EV. Before harvesting, cells were treated with 30 mmol/l MG-132 to preserve polyubiquitin chains of GRa, and GRa was subsequently precipitated as described above.
FBXW7 regulates glucocorticoid response in T-ALL A Malyukova et al induction in GRa activity after dexamethasone treatment (Figure 5a ). Consistent with this finding, activation of the MMTV reporter was repressed in cells transfected with WT-FBXW7, while transfection of T-ALL-derived mutant FBXW7 did not significantly alter MMTV reporter activity, compared with empty vector control. Thus, FBXW7 acted as a negative regulator of GRa and thereby modulated the response to GC treatment.
To gain a better understanding of the molecular basis for the enhanced cytostatic effect of GC in FBXW7-depleted cells, we performed gene expression analyses of Peer T-cells transduced with shFBXW7 or control viruses. Peer cells transduced with shFBXW7 or control viruses were treated with dexamethasone for 8 h, and gene expression was profiled using Affymetrix HuGene1 array. From 28 869 genes represented on the array, 327 were altered (X1.5 fold) upon dexamethasone treatment of Peer cells transduced with the control virus, with 25% being upregulated and 75% downregulated (Figure 5b ). FBXW7 depletion resulted in considerable changes in gene expression following dexamethasone treatment. We identified 645 genes with X1.5 fold change in expression in Peer cells transduced with shFBXW7 at 8 h postdexamethasone treatment. Among the 645 genes, 37% were upregulated and 63% were downregulated (log fold change X1.5, Pp0.01) (Figure 5b ). Among the genes that were significantly induced by dexamethasone alone, and further induced in FBXW7-depleted cells was the dexamethasone-responsive gene, TSC22D3 (GILZ), involved in the control of T-lymphocyte activation and apoptosis, the thioredoxin À interacting protein (TXNIP), which is a GC-regulated primary response gene involved in mediating GC-induced apoptosis, and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor a (NFKBIA), involved in the inhibition of the NFkB signaling pathway (Table 1) . Dexamethasone treatment of FBXW7-silenced cells also resulted in upregulation of several GR target genes with important functions in apoptosis control, such us BIM and PUMA (Table 1) . Gene Set Enrichment Analysis 31 was used to identify Gene Ontology classes specifically enriched in FBXW7-silenced cells treated with dexamethasone. A total of 383 Gene Ontology classes from the molecular signatures database C5 collection were enriched in the dexamethasone-treated shFBXW7 cells including metabolism (mitochondrion, mitochondrion organization and biogenesis, organelle envelope, mitochondrial transport, envelope, glucose metabolic process, mitochondrial envelope), RNA synthesis, rRNA processing (DNA directed RNA polymerase II holoenzyme, ribonucleoprotein complex, structural constituent of ribosome, ribosome, spliceosome, negative regulation of transcription factor activity, RNA processing) and regulation of apoptosis (Figure 5c ) at the P-value threshold of 0.001 and default false discovery rate cut off within gene set enrichment analysis of 0.25. However, at this cut off only 63 Gene Ontology classes were enriched in dexamethasone-treated cells. Significantly enriched Gene Ontology classes identified from this analysis were very similar for both gene sets, and were generally associated with lower false discovery rates and P-values in shFBXW7 cells treated with dexamethasone, compared with cells treated with dexamethasone alone (Figure 5c) .
A subset of the differentially expressed GC target genes involved in apoptosis (BIM, PUMA, TXNIP and NFKBIA) was further verified by qRT-PCR in shFBXW7-silenced Peer cells (Figure 5d ). To further validate our microarray data, we compared mean expression level of these GC target genes in four WT-FBXW7 and Mutant FBXW7 enhances the GC apoptotic signal via effects on BH3-only proteins Lastly, we examined the expression level of the pro-apoptotic proteins BIM and PUMA, and the antiapoptotic protein Mcl1, following dexamethasone treatment of K562 leukemia cells transduced with shFBXW7. In FBXW7-silenced K562 cells, with or without dexamethasone, we observed a marked increase in the levels of BIM and PUMA, but no change in Mcl1 protein level (Figure 6a ). We also compared BIM, PUMA, and Mcl1 protein levels following dexamethasone treatment in a single FBXW7-mutant human T-ALL xenograft (ALL-27), to three xenografts with WT-FBXW7 (ALL-30, 16, 31). We found increased PUMA and BIM levels in the mutant FBXW7 T-ALL xenografts, compared with WT-FBXW7 xenografts (Figure 6b ). Consistent with these data, we also observed increased BIM protein levels in dexamethasonetreated T-ALL cell lines with mutant FBXW7 (CEM, Molt4, Jurkat), compared with the Peer cell line with WT-FBXW7 (Figure 6c ). These results demonstrate that FBXW7 regulates GRa protein turnover and support a causal relationship between FBXW7 mutation status and GC sensitivity in T-ALL, where GC treatment of FBXW7-deficient cells potentiates expression of GRa-responsive pro-apoptotic genes.
DISSCUSSION
Inactivation of FBXW7 has been linked to tumor development, as a tumor suppressor function by targeting oncoproteins for proteasomal degradation. 1 The phenotypic outcome associated with FBXW7 deficiency has also been reported to depend on cell type. [32] [33] [34] However, inactivation of FBXW7 by the loss of expression or mutation was associated with favorable prognosis in primary breast cancer, 35 and with good prognosis and early GC treatment response in childhood T-ALL [2] [3] [4] [5] [6] [7] [8] Here, we have shown that, while FBXW7 loss of function in T-ALL may contribute to the malignant phenotype before diagnosis, it then functions as a treatment sensitizer in the synthetic environment of GC treatment.
The GR is a critical target in chemotherapy protocols used to treat ALL, however, very little is known about the processes that regulate GR stability and activity. Studies have confirmed that GC sensitivity could be restored through overexpression of GR in FBXW7 regulates glucocorticoid response in T-ALL A Malyukova et al GC-resistant ALL cells, [36] [37] [38] and suggested that GC resistance may be linked to GR expression levels. However, other studies have shown that GC resistance in ALL can also occur downstream of ligand-induced translocation of GR. 21, 22 In the present study, we demonstrate that FBXW7 interacts with GRa through a conserved, GSK3b phosphorylated degron in GRa, promoting its ubiquitylation and proteasomal degradation. GR protein stability has been reported to be a crucial factor in determining its transcriptional activity. 39 We found that knockdown of FBXW7 in leukemic cells promoted the expression of several GC responsive pro-apoptotic target genes, and accordingly, enhanced GC sensitivity in GC resistant T-ALL cells. Our microarray studies also correlate with previously published results on GC-induced transcriptional response. 40, 41 Notably, inactivation of FBXW7 by shRNA resulted in enhanced induction or repression of a substantial number of dexamethasoneregulated genes. Among the genes that were further induced in shFBXW7/DEX T-ALL cells were the GC target genes: BCL211/BIM, BBC3/PUMA, TXNIP, NFKBIA, TSC22D3/GILZ. The expression of these genes was also induced in FBXW7-mutated T-ALL xenografts. Thus, these results suggest that FBXW7 inactivation in T-ALL reinforces the transcriptional response to GC, through a reduced rate of degradation of GR in T-ALL cells.
Besides elevated levels of the GR protein, we also found increased protein expression of the pro-apoptotic proteins BIM and PUMA in FBXW7-deficient cells. Accumulating evidence suggests that dexamethasone-induced apoptosis in lymphocytes is executed through the intrinsic pathway, which involves activation of pro-apoptotic factors, loss of mitochondrial transmembrane potential and subsequent activation of caspases.
14 A number of recent studies have identified BIM and PUMA as crucial factors for initiating apoptosis induced by GR, 22, [42] [43] [44] but the mechanism, by which GCs regulate BIM and PUMA expression in lymphoid cells is poorly understood. Mechanisms involving transcriptional activation of BIM and/or PUMA by GR in T-ALL cell lines and primary thymocytes have been suggested, 40, 43, 45 but induction of apoptosis through interaction of GSK3b-BIM upon dexamethasone treatment has also been proposed. 46 Our data on BIM upregulation in FBXW7-deficient T-ALL cell lines are consistent with the increased sensitivity to GC in these cells. The molecular mechanism behind upregulation of BIM in FBXW7-deficient cells remains to be determined, but our data suggest that increased GRa activity results in enhanced BIM expression, although we cannot exclude the possibility that upregulation of other FBXW7 substrates like c-Myc or c-Jun may also result in increased BIM and/or PUMA expression. 47, 48 We propose a model in normal cells, whereby phosphorylation of GRa by GSK3b triggers the ubiquitylation of GRa and terminates GC-dependent GRa signaling. Our study suggests that the functional inactivation of FBXW7 might specifically sensitize leukemic cells to apoptosis in response to dexamethasone, through increased GR protein stability and expression of GR target genes such as BIM and PUMA. Cells with mutant FBXW7 in physiological conditions survive and evade apoptosis through the activation of Mcl1 and/or NFkB2. [49] [50] [51] [52] In our model, enhanced GR protein stability and induction of BIM and PUMA in FBXW7-deficient leukemic cells will predispose these cells to apoptosis, whereas Mcl1 protein expression was not altered.
To our knowledge, these findings are the first to show that loss-of-function mutation of a protein, which acts as a tumor suppressor in other contexts can provide a synthetic lethal environment in the presence of GCs. Our results provide important new insights into the complex interactions between putative tumor suppressors and the therapeutic environment of cancer cells and suggest that therapeutic attempts to reactivate the mutant FBXW7 function may create treatment resistance in specific instances. Importantly, the results suggest that blocking the function of wild-type FBXW7 in T-ALL cells may have greater overall therapeutic benefit by enhancing GC sensitivity.
